MaxCyte Inc (NASDAQ:MXCT) price on current trading day, fall -2.21% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $3.54.
A look at the stock’s price movement, the close in the last trading session was $3.62. Turning to its 52-week performance, $5.26 and $3.16 were the 52-week high and 52-week low respectively. Overall, MXCT moved -21.68% over the past month.
MaxCyte Inc’s market cap currently stands at around $373.41 million, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 7.98M for the company’s revenue for the quarter, with a low and high estimate of 7.46M and 8.4M respectively. The average forecast suggests down to a -49.08% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 38.18M, representing a -7.54% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that MXCT is a Hold. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 1 recommend MXCT as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
MXCT’s current price about -15.46% and -18.53% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 28.50, while 7-day volatility ratio is 6.74% and 5.59% in the 30-day chart. Further, MaxCyte Inc (MXCT) has a beta value of 0, and an average true range (ATR) of 0.24. Analysts have given the company’s stock an average 52-week price target of $8, forecast between a low of $8 and high of $8. Looking at the price targets, the low is -125.99% off current price level while to achieve the yearly target high, price needs to move -125.99%. Nonetheless, investors will most likely welcome a -125.99% jump to $8 which is the analysts’ median price.
If we refocus on MaxCyte Inc (NASDAQ:MXCT), historical trading data shows that trading volumes averaged 533.54K over the past 3 months. The company’s latest data on shares outstanding shows there are 105.30 million shares.
The 7.71% of MaxCyte Inc’s shares are in the hands of company insiders while institutional holders own 71.43% of the company’s shares. Current price change has pushed the stock -14.90% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MXCT stock continues to rise going into the next quarter.
